Pharmaceutical Research and Manufacturers of America (PhRMA)
PhRMA, the Pharmaceutical Research and Manufacturers of America, represents the country’s leading innovative biopharmaceutical research companies. Their members are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. New medicines are an integral part of the health care system, providing doctors and patients with safe and effective treatment options, and improving quality of life.
PhRMA was formed in 1958 to represent America’s biopharmaceutical research companies and help promote smart public policy that supports medical research to address patient needs. Headquartered in Washington, D.C., with offices in leading biopharmaceutical research communities, PhRMA advocates in the United States and around the world for policies that support the discovery and development of innovative medicines. Their policy priorities include: explaining the increased complexity and risk of the research and development process; reinforcing the need for investment in R&D; ensuring broad access to and appropriate use of medicines; and emphasizing the importance of strong intellectual property incentives for new medicines.
Their mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, they are dedicated to achieving these goals in Washington, D.C. and across the country.
Key Facts about the Biopharmaceutical Industry:
- In 2015, PhRMA member companies invested $58.8 billion in research in development of new medicines and over half a trillion dollars since 2000.
- America’s biopharmaceutical industry is the global leader in medical innovation, with more than 500 new medicines approved by the Food and Drug Administration since 2000.
- The biopharmaceutical pipeline has over 7,000 new medicines currently in development around the world.